http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Min Joo,Lee, Kwan Jae,Hwang, Ji-Yeon,Lee, Hye Seung,Chio, Sung Hee,Lim, Soo,Jang, Hak Chul,Park, Young Joo Japan Endocrine Society 2013 Endocrine journal Vol.60 No.10
<P>Small heterodimer partner (SHP) is involved in bile, lipid, and glucose metabolism. The aim of this study was to investigate the effect of SHP on the development of atherosclerosis. Apolipoprotein E knockout (ApoE-/-) mice were crossed with SHP knockout (SHP-/-) mice to generate double knockout (ApoE-/-SHP-/-) mice. ApoE-/- and ApoE-/-SHP-/- male mice were fed a western diet for 20 weeks. Body weight in ApoE-/-SHP-/) mice was significantly lower than that in ApoE-/- mice (371 g vs. 421 g, p<0.01). Loss of SHP in ApoE-/- mice decreased the size of adipocytes in white adipose tissue and reduced lipid accumulation in the liver. Glucose intolerance was improved in ApoE-/-SHP-/- mice as compared with ApoE-/- mice (p<0.01). There was no statistical difference in non-high density lipoprotein cholesterol levels between ApoE-/-SHP-/- mice and ApoE-/- mice despite an increase of cholesterol 7α-hydroxylase expression in the liver. The proportion of atherosclerotic lesions in the aorta was significantly lower in ApoE-/-SHP-/- mice than in ApoE-/- mice (2.82.0% vs. 9.11.9%, p<0.01). In conclusion, loss of SHP function can prevent atherosclerosis, and resistance to diet-induced obesity is the primary factor contributing to this protective effect.</P>
Park, Do Joon,Lim, Jung Ah,Kim, Tae Hyuk,Choi, Hoon Sung,Ahn, Hwa Young,Lee, Eun Kyung,Lee, You Jin,Kim, Kyung Won,Park, Young Joo,Yi, Ka Hee,Cho, Bo Youn Japan Endocrine Society 2012 Endocrine journal Vol.59 No.11
<P>The best treatment option for recurrent papillary thyroid carcinoma (PTC) is reoperation when the recurrent lesion is locoregional. The prognostic significance of serum thyroglobulin (Tg) levels before reoperation and the association between the outcome of reoperation and Tg level remain unclear. Our study aimed to determine the outcomes of patients who underwent reoperation and their association with serum Tg levels. We retrospectively studied 79 patients with PTC with locoregional recurrence whose whole-body scan results were negative for any recurrence but whose serum Tg levels were detectable after first-line treatment. All the patients underwent reoperation and follow-up examinations, which involved serial serum Tg measurements after thyroxine withdrawal (T4-off Tg), neck ultrasonography, chest computed tomography, and/or fluorodeoxyglucose-positron emission tomography, to detect further recurrence. During the median follow-up duration of 89 months (range, 38-332 months), 30 patients (38.0%) experienced a second recurrence even after the reoperation. Among all patients, only 12 whose Tg levels decreased postoperatively to undetectable levels showed no recurrence. Most recurrences were detected in the patients with high T4-off Tg levels after the reoperation (T4-off Tg level (ng/mL), number of patients with recurrence, %: <1, 0/12, 0%; 1-10, 9/31, 33.3%; >10, 16/22, 72.7%; P < 0.001). In conclusion, recurrence occurred in 38.0% of the patients even after the reoperation. The postoperative T4-off Tg level was a good indicator of recurrence after the reoperation. Therefore, patients who experience recurrence should undergo follow-up examinations that involve routine measurements of T4-off Tg levels, especially when postreoperative values exceed 10 ng/mL.</P>
Irbesartan prevents myocardial remodeling in experimental thyrotoxic cardiomyopathy.
Kim, Bo Hyun,Cho, Kyoung Im,Kim, Seong Man,Kim, Jee-Yeon,Choi, Bo Gwang,Kang, Ji Hyun,Jeon, Yun Kyung,Kim, Sang Soo,Kim, Seong-Jang,Kim, Yong Ki,Kim, In Joo Japan Endocrine Society 2012 Endocrine journal Vol.59 No.10
<P>This study evaluated the effects of irbesartan and propranolol on thyroid hormone (TH)-induced cardiac functional and structural remodeling. A rat model of thyrotoxicosis was established by daily intraperitoneal injections of L-thyroxine (T(4), 100 μg/kg) for 4 weeks. Forty Sprague-Dawley rats were randomly divided into four groups (n = 10 each): control group, T(4) group (T(4) alone), T(4) plus irbesartan group (T(4)-Irb, 30 mg/kg), and T(4) plus propranolol group (T(4)-Pro, 0.5mg/mL of drinking water). Cardiac chamber size and functional parameters were measured by echocardiography and cardiomyocyte diameter. Heart rate (HR) and cardiac fibrosis were determined. T(4) alone showed significantly increased HR and cardiomyocyte width (25.0 1.77 vs. 18.8 0.84 μm, P < 0.001) with fibrosis, reduced left ventricle (LV) longitudinal strain (S(long); -16.0 6.27 vs. -22.7 5.19 %, P < 0.001) compared with control. When compared with T(4) alone, T(4)-Irb showed significantly improved LV S(long) (-21.4 1.84 vs. -16.0 6.27 %, P =0.017) and reduced cardiomyocyte width (21.0 1.0 vs. 25.0 1.77 μm, P =0.002) with comparable HR (458.4 24.3 vs. 486.6 30.1 bpm, P = 0.086). However, T(4)-Pro showed significantly reduced HR with improved LV S(long) without alteration of cardiomyocyte width and fibrosis compared with T(4) alone. In conclusion, renin-angiotensin system (RAS) blocking by irbesartan could significantly attenuate TH-induced cardiac structural and functional remodeling. However, HR reduction by propranolol could not alternate structural remodeling, which may implicate the RAS as having an important role in thyrotoxic cardiomyopathy beyond tachycardia.</P>
Park, S.K.,Choi, W.J.,Oh, C.-M.,Kim, J.,Shin, H.,Ryoo, J.-H. THE JAPAN ENDOCRINE SOCIETY 2014 Endocrine journal Vol.61 No.3
Elevated serum ferritin levels are associated with insulin resistance, type 2 diabetes, cardiovascular disease, and metabolic syndrome. To date, however, no cohort studies have examined whether serum ferritin levels are an independent risk factor for the obesity. Therefore, we conducted a prospective cohort study to evaluate the temporal relationship between serum ferritin levels and obesity development in Korean men. Total 17,812 healthy Korean men who participated in a medical health check-up program in 2005 were followed-up until 2010. Obesity was defined as a body mass index >= 25 kg/m(2). Cox proportional hazards model was used to measure the hazard ratio of the quartile groups of serum ferritin levels. During 64,446.5 person-years of follow-up carried out, 2,627 patients became obese. After adjusting for multiple covariates, we found that the hazard ratios (95% confidence interval) for incident obesity when we compared the second, third and fourth quartiles of serum ferritin levels with the first quartile were 1.08 (0.95-1.23), 1.14 (1.00-1.30), and 1.24 (1.09-1.41), respectively (p for trend = 0.003). Both severe obesity (body mass index >= 30 kg/m(2)) and abdominal obesity based on waist circumference (>90 cm) showed consistent longitudinal associations (p for trend <0.001). Elevated serum ferritin levels may have been a predictive factor for obesity during the 5-year follow-up in 17,812 Korean men.
KIM, Soo-Kyung,KIM, Hae-Jin,AHN, Chul-Woo,PARK, Seok-Won,CHO, Yong-Wook,LIM, Sung-Kil,LEE, Hyun-Chul,CHA, Bong-Soo The Japan Endocrine Society 2008 Endocrine journal Vol.55 No.6
<P>Leptin has been linked to adiposity, insulin resistance, and coronary artery disease (CAD). We examined whether the leptin concentrations are associated with the risk of CAD and metabolic syndrome (MS). The plasma leptin concentrations were measured in 556 diabetic patients (341 men and 215 women). The odds ratio (OR) of CAD and MS were increased on moving from the lowest quartile (Q1) of leptin concentration to the highest quartile (Q4) and remained significant after adjusting for age, sex, BMI, concentrations of total cholesterol, triglyceride, or high-sensitivity C-reactive protein (hsCRP), and treatment modalities for hyperglycemia. The frequency of CAD was highest in the insulin resistant group (Q4 of homeostasis model assessment-insulin resistance index [HOMA-IR]) at Q4 of leptin concentration (34.5%), compared with that of Q4 of leptin (26.4%) or HOMA-IR (21.9%). In multivariate analysis, plasma leptin concentration was identified as the most significantly independent predictor for CAD (OR 10.24, 95% CI 3.01 to 45.05). Other variables with associated with CAD were age, sex, hypertension, low-HDL cholesterolemia, and hsCRP. In conclusion, hyperleptinemia might be an independent risk factor for CAD and MS in diabetic subjects. And the simultaneous measurement of insulin resistance and leptin concentration might be helpful for screening subjects with a high-risk of CAD.</P>
YOUN, Jong Chan,RHEE, Yumie,PARK, Soo Young,KIM, Won Ho,KIM, Soo Jung,CHUNG, Hyun Cheol,HONG, Soon Won,LIM, Sung-Kil The Japan Endocrine Society 2006 Endocrine journal Vol.53 No.3
<P>An 85-year-old man who had undergone a right hemicolectomy for colon cancer presented with severe hypothyroidism and hoarseness 21 months after the operation. The serum thyrotropin (TSH) was markedly elevated to 118.14 μIU/mL and serum free thyroxine (fT4) level was markedly suppressed to 0.34 ng/dL. Symptoms of hoarseness and neck swelling were already evident 4 months prior at which time tests for normal thyroid function were performed. The patient was referred due to aggravated pain on his diffusely enlarged hard goiter. An enlarged thyroid with some calcification was noticed in the neck ultrasonography with multiple cervical lymphadenopathies. Core biopsy of the thyroid gland showed invasion of poorly differentiated adenocarcinoma cells. Immunohistochemical studies showed positive staining only for carcinoembryonic antigen (CEA). There were multiple lung parenchymal nodules and adrenal masses at the time of evaluation. The patient was started on palliative chemotherapy with thyroid hormone replacement and gradually became euthyroid. From these findings and the clinical observations, thyroid metastasis with hypothyroidism developing acutely from metastatic colon adenocarcinoma was diagnosed.</P>